IPS Biopharma
SHARE
Share on facebook
Share on twitter
Share on linkedin
Share on email
IPS Biopharma AG is a privately held, Swiss immuno-oncology focused biotech company developing a potentially first-in-class immunotherapy for solid tumor cancers. The company’s lead drug candidate, IP-001, is designed to initiate a patient-specific, well-tolerated, systemically active immune response against a patient’s individual cancer. IP-001, also known as N-dihydrogalactochitosan, is injected intratumorally after a standard-of-care tumor ablation to initiate the immunotherapy. Unique molecular properties and the novel mechanism of action enables IP-001 to trap and retain tumor-targeting information and promote a robust immune response that attacks both the ablated tumor and distant metastases.

Encouraging early clinical data showed shrinkage of both local tumors and distant metastases after ablation + IP-001 treatment. In some patients, this led to elimination of the cancer with long-lasting response. The company has partnered with the Swiss Group for Clinical Cancer Research (SAKK) for clinical trial development and implementation of its Swiss phase I/II multicenter study that addresses significant clinical unmet need in various indications.

IPS Biopharma AG is an Immunophotonics subsidiary and is supported by the Swiss Foundation for Technological Innovation (STI), be-advanced, the Berne Economic Development Agency (BEDA), is located in the Switzerland Innovation Park and is an active part of the startup community in Switzerland.

Mehr News & Events

Coworking Space im SIPBB

In der Serie «Raumangebot» führen wir Sie in regelmässigen Abständen durch den Neubau von SIPBB.

Labore und Forschungsflächen im SIPBB

In der Serie «Raumangebot» führen wir Sie in regelmässigen Abständen durch den Neubau von SIPBB.

Neugestaltung / Réaménagement Marcelin-Chipot Strasse

Der Switzerland Innovation Park Biel/Bienne soll eine attraktive Umgebung mit Bäumen und Sitzgelegenheiten erhalten. Gemäss Medienmitteilung vom 23...

This website uses cookies to ensure you get the best experience on our website. By continuing you agree with the our terms of use.